Employees: 1,306
Size DongKook Pharmaceutical (086450.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $855M, the 264th largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩24,400 on 18 Nov 2026.
Performance Over six months the shares gained 8.9%, against -22.0% for the median peer and -37.2% for the South Korea market (cap-weighted) — 2nd highest of 19 in its peer set.
Growth Revenue grew 13.0% over the last twelve months (peer median +3.6%); the operating margin is 10.0% (peer median 2.7%).
Valuation It trades at 14.0× forward earnings against a peer median of 24.7× (4th cheapest of 9).
Price implies For today's price to make sense, revenue must grow about -4% a year for seven years (Req g). Recent delivered growth is +11%, so the hurdle is -15 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 3.0 points above its cost of capital (5.5% WACC).
Next results Next results expected around 18 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩1.01T | ₩927B | ₩812B | ₩731B | ₩662B |
| Revenue growth | — | +14% | +11% | +10% | — |
| Gross profit | ₩549B | ₩492B | ₩440B | ₩405B | ₩375B |
| EBITDA | ₩136B | ₩128B | ₩108B | ₩88.0B | ₩91.4B |
| Net income | ₩69.7B | ₩66.0B | ₩61.2B | ₩47.2B | ₩52.9B |
| Free cash flow | ₩27.7B | ₩29.5B | ₩50.9B | ₩9.64B | ₩1.99B |
| Capital expenditure | ₩69.1B | ₩46.0B | ₩30.8B | ₩39.4B | ₩51.2B |
| Total debt | ₩71.1B | ₩76.2B | ₩80.7B | ₩105B | ₩91.4B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 086450.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -2.6% | -10.3% | 9th highest of 21 |
| 6-month return | +8.9% | -22.0% | 2nd highest of 19 |
| Distance from 52-week high | -21.9% | -42.6% | 3rd highest of 21 |
| Revenue growth (TTM) | +13.0% | +3.6% | 7th highest of 19 |
| Operating margin | 10.0% | 2.7% | 6th highest of 19 |
| Forward P/E | 14.0× | 24.7× | 4th cheapest of 9 |
| Growth the price implies (Req g, 7 yrs) | -4.2% | 11.2% | 2nd least demanding of 9 |
| Growth delivered (Del g) | +10.6% | +8.3% | 5th highest of 9 |
| Hurdle (Req g minus delivered) | -14.8 pp | -5.9 pp | 3rd least demanding of 9 |
| ROIC minus cost of capital | +3.0 pp | -2.9 pp | 3rd highest of 17 |
| EV / EBITDA | 8.8× | 8.4× | 4th most expensive of 8 |
| Net debt / EBITDA | -0.3× | 1.8× | 4th least indebted of 8 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| DongKook Pharmaceutical 086450.KS | South Korea | $855M | +9% | +13% | 10% | 14.0× | -4.2% | +10.6% |
| Daewoong Pharm 069620.KS | South Korea | $856M | -33% | +9% | 12% | 9.0× | n/a | n/a |
| Jiangsu Yahong Meditech 688176.SS | China | $854M | -20% | +15% | -172% | n/a | n/a | n/a |
| Corvus Pharmaceuticals CRVS | United States | $860M | -16% | n/a | n/a | n/a | n/a | n/a |
| Kaken Pharmaceutical 4521.T | Japan | $860M | -8% | +5% | 10% | 21.4× | n/a | n/a |
| City Therapeutics CTY | United States | $861M | n/a | +388% | -442% | n/a | n/a | n/a |
| Beijing Sun-Novo Pharmaceutical Research 688621.SS | China | $849M | -8% | -1% | -2% | 29.0× | n/a | n/a |
| GuangYuYuan Chinese Herbal Medicine 600771.SS | China | $866M | -26% | -6% | 5% | 38.3× | 31.7% | +4.2% |
| SK Discovery 006120.KS | South Korea | $866M | +25% | +24% | 3% | n/a | n/a | n/a |
| Pharming PHARM.AS | Netherlands | $867M | -6% | +2% | 9% | 34.9× | 2.4% | +12.4% |
| Sanofi Consumer Healthcare India SANOFICONR.NS | India | $869M | -26% | +23% | 36% | 28.1× | 17.7% | +22.7% |
| Hunan Er-Kang Pharmaceutical 300267.SZ | China | $829M | -40% | -14% | -29% | n/a | n/a | n/a |
| Latigo Biotherapeutics LTGO | United States | $882M | n/a | n/a | n/a | n/a | n/a | n/a |
| Dezhan Healthcare 000813.SZ | China | $825M | -33% | -10% | -121% | n/a | n/a | n/a |
| Zhejiang Ausun Pharmaceutical 603229.SS | China | $824M | -34% | +1% | 0% | n/a | n/a | n/a |
| Wanbangde Pharmaceutical 002082.SZ | China | $823M | -52% | -38% | -10% | n/a | 27.7% | -39.5% |
| Northeast Pharmaceutical 000597.SZ | China | $895M | -14% | -6% | 3% | n/a | -7.6% | -0.7% |
| Aktis Oncology AKTS | United States | $895M | -15% | +337% | -837% | n/a | n/a | n/a |
| Hygeia Healthcare 6078.HK | Hong Kong | $811M | -3% | +2% | 14% | 10.4× | 4.6% | +22.5% |
| Sichuan Huiyu Pharmaceutical 688553.SS | China | $904M | -28% | +14% | 7% | n/a | 19.4% | -6.0% |
| Collegium Pharmaceutical COLL | United States | $806M | -24% | +8% | 15% | 3.7× | -2.6% | +20.3% |